- Home
- AKBA vs CMP Comparison
AKBA vs CMP Comparison
Compare AKBA & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- CMP
- Stock Information
- Founded
- AKBA 2007
- CMP 1993
- Country
- AKBA United States
- CMP United States
- Employees
- AKBA N/A
- CMP N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- CMP Other Metals and Minerals
- Sector
- AKBA Health Care
- CMP Basic Materials
- Exchange
- AKBA Nasdaq
- CMP Nasdaq
- Market Cap
- AKBA 958.6M
- CMP 836.2M
- IPO Year
- AKBA 2014
- CMP 2003
- Fundamental
- Price
- AKBA $3.66
- CMP $19.76
- Analyst Decision
- AKBA Strong Buy
- CMP Buy
- Analyst Count
- AKBA 5
- CMP 3
- Target Price
- AKBA $6.90
- CMP $19.00
- AVG Volume (30 Days)
- AKBA 3.2M
- CMP 514.5K
- Earning Date
- AKBA 08-07-2025
- CMP 09-16-2025
- Dividend Yield
- AKBA N/A
- CMP N/A
- EPS Growth
- AKBA N/A
- CMP N/A
- EPS
- AKBA N/A
- CMP N/A
- Revenue
- AKBA $184,909,000.00
- CMP $1,213,500,000.00
- Revenue This Year
- AKBA $26.88
- CMP $11.60
- Revenue Next Year
- AKBA $44.34
- CMP $2.33
- P/E Ratio
- AKBA N/A
- CMP N/A
- Revenue Growth
- AKBA N/A
- CMP 5.81
- 52 Week Low
- AKBA $1.07
- CMP $7.51
- 52 Week High
- AKBA $4.08
- CMP $22.69
- Technical
- Relative Strength Index (RSI)
- AKBA 48.61
- CMP 40.29
- Support Level
- AKBA $3.47
- CMP $20.31
- Resistance Level
- AKBA $4.04
- CMP $20.67
- Average True Range (ATR)
- AKBA 0.17
- CMP 0.69
- MACD
- AKBA -0.06
- CMP -0.29
- Stochastic Oscillator
- AKBA 31.20
- CMP 5.48
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.